After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...